New Analyses Previewed for AHA 2026 in Transthyretin Amyloid Cardiomyopathy
Researchers are preparing new clinical trial analyses and diagnostic frameworks for the upcoming American Heart Association Scientific Sessions, focusing on transthyretin amyloid cardiomyopathy (ATTR-CM). Joshua D. Mitchell, MD, MSCI, previewed forthcoming data from the HELIOS-B trial of vutrisiran and the CARDIO-TTRansform trial of eplontersen, according to Medscape. The presentations will expand on cardiovascular outcomes, exercise capacity, and advanced imaging techniques as the medical community looks toward future management strategies for the condition.
HELIOS-B Open-Label Extension and Exercise Testing
The HELIOS-B trial will report its two-year open-label extension data at the meeting. Investigators will also present a detailed exercise-capacity analysis utilizing cardiopulmonary exercise testing and stress echocardiography. These assessments aim to measure functional changes over time in patients receiving vutrisiran, offering a clearer picture of long-term mobility and cardiovascular performance.
CARDIO-TTRansform Imaging and Mechanistic Studies
CARDIO-TTRansform will share focused echocardiographic and cardiac magnetic resonance analyses to characterize treatment effects associated with eplontersen. Alongside these cardiac imaging findings, mechanistic studies will explore inflammation and myocardial fibrosis using targeted positron emission tomography (PET) tracers. These investigations seek to broaden the understanding of ATTR-CM pathology beyond traditional amyloid-fibril deposition.
Specialty Center Diagnostics and Multidisciplinary Care
Diagnostic advancements will take center stage through the AHA-led IMPACT ATTR initiative, which will release diagnostic best practices gathered from 10 specialized US centers. Additional sessions will highlight the role of artificial intelligence, multimodality imaging, and findings from the REVEAL study. Broader conference programming will evaluate current ATTR-directed therapies, heart failure management protocols, and multidisciplinary care models designed to streamline patient evaluation.
Frequently Asked Questions
What specific treatments are evaluated in the previewed analyses?
The upcoming presentations feature data on vutrisiran from the HELIOS-B trial and eplontersen from the CARDIO-TTRansform trial, both targeting transthyretin amyloid cardiomyopathy.
What imaging modalities are researchers using to study myocardial fibrosis?
Investigators are utilizing targeted positron emission tomography (PET) tracers, alongside cardiac magnetic resonance and stress echocardiography, to assess inflammation and fibrosis.
Which initiative is sharing diagnostic best practices from US specialty centers?
The AHA-led IMPACT ATTR initiative is sharing diagnostic best practices derived from 10 specialty centers across the United States.
Worth a look